Nature Outlook 

The future of medicine

Modern medicine is affording people longer and healthier lives. But researchers want to take improvements in health even further. With advances in gene editing, technology to overcome paralysis and efforts to address high drug costs, the future of medicine is bright.

This Nature Outlook is editorially independent. It is produced with third party financial support. About this content.

This Nature Outlook is editorially independent, produced with financial support from a third party. About this content.

Nature is pleased to acknowledge the financial support of Merck in producing this Outlook. The sponsor retains sole responsibility for the following message.

Merck, the world’s oldest pharmaceutical and chemical company, is celebrating its three-hundred-and-fiftieth anniversary in 2018. Over 350 years, Merck has evolved into a leading global science and technology company in healthcare, life science and performance materials. To mark its anniversary, Merck is sponsoring this Nature Outlook on the future of medicine.

The Merck family has remained the majority owner of the company, which employs approximately 50,000 people around the world. Merck develops technologies that improve and enhance life, such as biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, and liquid crystals for smartphones and LCD televisions. Merck invests more than €1.7billion in biopharmaceutical research and development (R&D) each year.

As the world’s oldest pharmaceutical and chemical company, Merck can look back at a successful 350-year history of curiosity and innovation. It is our privilege and honour to continue this path into the future combined with an invitation to partners all over the world to join forces and to work together with us to advance science, technology and medicine for the benefit of patients.

Read the sponsor’s article.

For more information about Merck, please visit